Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

NCT07011550 · clinicaltrials.gov ↗

PHASE2

Phase

SUSPENDED

Status

7

Enrollment

OTHER

Sponsor class

Stopped PI Request

Conditions

Microsatellite-stable Colorectal Cancer
Standard of Care
Nivolumab
Bevacizumab

Interventions

DRUG: Nivolumab
DRUG: Bevacizumab
DRUG: BMS-986340
DRUG: Trifluridine + Tipiracil

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]